Search
Aurothioglucose
go.drugbank.com/drugs/DB09121ApprovedWithdrawncompounds that were indicated for rheumatoid arthritis therapy have since been replaced with the use of various current disease modifying anti-rheumatic drugs (DMARDs) like methotrexate and others, which are far
Gepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigational[L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients. … [L52680,L52685] In December later the same year, the FDA approved another indication for gepotidacin for the treatment of uncomplicated urogenital gonorrhea. [L54803]
Sulfadoxine
go.drugbank.com/drugs/DB01299ApprovedInvestigationalWithdrawnA long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.
Tetracaine
go.drugbank.com/drugs/DB09085ApprovedInvestigationalVet approvedTetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch.
Aprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigational[A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy. … [A263386] Patients with resistant hypertension are at an increased risk of cardiovascular and renal events[A263386] and have traditionally had limited additional treatment options.
Vilanterol
go.drugbank.com/drugs/DB09082ApprovedInvestigational[A7737] This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). … [L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.
Anisindione
go.drugbank.com/drugs/DB01125ApprovedAnisindione is a synthetic anticoagulant and an indanedione derivative.
Tocilizumab
go.drugbank.com/drugs/DB06273ApprovedInvestigational[L44483] Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023.[L48385]. … [L40164] Subsequently, it was granted approval by Health Canada and the FDA in October [L43697] and December 2022, respectively.
Phenoxyethanol
go.drugbank.com/drugs/DB11304ApprovedInvestigationalIt is produced by reacting phenol (EU) and ethylene oxide (EU) at a high temperature and pressure. This substance occurs naturally in green tea (EU) [L2621]. … Phenoxyethanol has been classified as an antimicrobial and preservative by Health Canada [L2623].
Avelumab
go.drugbank.com/drugs/DB11945ApprovedInvestigational[A261496] Avelumab was first approved by the FDA on March 23, 2017.